1687PReal-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma

ConclusionsCurrently available systemic therapies are not specific for advanced ES, have a limited response durability and low tolerability. This is the largest US-based rw study that provides benchmarking treatment efficacy and safety data for development of standard of care therapies for ES. Table:1687P Real-world outcomes by line of therapy1L N  = 742L+ N = 46rwORR (95% CI), %14.9 (7.7-25.0)9.4 (4.4-17.1)Median rwDOR (95% CI), wks14.5 (9.1-22.6)19.6 (3.1-24.3)rwDCR (95% CI), %20.3 (11.8-31.2)19.8 (12.4-29.2)Median rwPFS (95% CI), wks11.0 (7.3-29.9)26.0 (13.9-32.0)Median OS (95% CI), wks66.3 (49.6-94.1)43.3 (33.6-78.3)Legal entity responsible for the studyEpizyme, Inc.FundingEpizyme, Inc.DisclosureM.M. Gounder: Advisory / Consultancy, Travel / Accommodation / Expenses: Epizyme; Honoraria (self), Advisory / Consultancy: Karyopharm; Honoraria (self), Advisory / Consultancy: Daiichi; Honoraria (self): TRACON; Honoraria (self): Amgen. P. Merriam: Advisory / Consultancy: Lilly. S.R. Patel: Advisory / Consultancy, Research grant / Funding (self): Janssen; Advisory / Consultancy: PharmaMar; Advisory / Consultancy: MJ Hennessey/Onc Live; Advisory / Consultancy: Novartis; Advisory / Consultancy: Immune D; Research grant / Funding (self): Eisai; Research grant / Funding (self): Blueprint Medicines; Research grant / Funding (self): Bavarian Nordic. R. Chugh: Advisory / Consultancy: Epizyme, Janssen ,EMD Serono; Research grant / Funding (institution): AADi (Institution), Novart...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research